FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172520466> ?p ?o ?g. }

• W3172520466 abstract "Background Type 2 diabetes (T2D) is associated with an increased risk of heart failure (HF) and cardiovascular (CV) mortality. Sodium–glucose-cotransporter-2 (SGLT2) inhibitors reduce the risk of major adverse CV events and hospitalization for HF in T2D patients with high cardiovascular risk, despite only a modest improvement in glycaemic control. Restoring cellular energy homeostasis and reversing adverse cardiac remodelling in diabetes have been speculated as a potential metabolic modulatory effect of SGLT2 inhibitors leading to their beneficial CV outcomes. Myocardial energy deficient states can be detected non-invasively by 31-phosphorus magnetic resonance spectroscopy (31P-MRS). Objectives Utilising cardiovascular magnetic resonance imaging (CMR) and 31P-MRS in a single centre longitudinal cohort study, we aimed to investigate the effects of the selective SGLT2 inhibitor empagliflozin on myocardial energetics, function, perfusion, and myocardial cellular volume in patients with T2D. Methods Eighteen consecutive T2D patients who were commenced on empagliflozin in cardiometabolic optimisation clinics underwent CMR and 31P-MRS scans before and after twelve-week empagliflozin treatment, and plasma N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) levels were measured. (Table 1) Ten controls with no diabetes underwent an identical 31P-MRS and CMR protocol on a single visit. Results When compared to controls, patients with T2D showed: lower myocardial energetics (1.52±0.40 vs 2.20±0.5, p=0.0005), lower stress myocardial blood flow (1.60±0.50 vs 2.10±0.50, p=0.02) and lower left ventricular ejection fraction (52±13% vs 63±4%, p=0.01). Treatment with empagliflozin led to significant improvements in myocardial energetics (PCr/ATP: 1.52 to 1.76, p=0.009). This was accompanied by a relative 13% improvement in left ventricular ejection fraction (p=0.001), 3% improvement in global longitudinal strain (p=0.01), 61% reduction in NTproBNP (p=0.05), and 9% reduction in myocardial cell volume (p=0.04). No significant change in myocardial blood flow or diastolic strain was detected (table 1). Conclusions Empagliflizon improves myocardial energetics and function, reduces myocardial cellular volume, and reduces NT-proBNP levels in patients with T2D (figure 1). This study, by using the myocardial phosphocreatine to ATP ratio to monitor the early energetic response of the heart to treatment, and CMR to monitor structural and functional changes, provides significant novel insights into potential mechanisms by which empagliflozin exerts its beneficial cardiovascular effects. Conflict of Interest NONE" @default.
• W3172520466 created "2021-06-22" @default.
• W3172520466 creator A5004676254 @default.
• W3172520466 creator A5012112944 @default.
• W3172520466 creator A5012346596 @default.
• W3172520466 creator A5012429282 @default.
• W3172520466 creator A5036372511 @default.
• W3172520466 creator A5036774695 @default.
• W3172520466 creator A5038761588 @default.
• W3172520466 creator A5043214675 @default.
• W3172520466 creator A5057585729 @default.
• W3172520466 creator A5063579369 @default.
• W3172520466 creator A5078715263 @default.
• W3172520466 creator A5087261864 @default.
• W3172520466 date "2021-06-01" @default.
• W3172520466 modified "2023-09-27" @default.
• W3172520466 title "154 Empaglifozin on cardiac energetics and function" @default.
• W3172520466 doi "https://doi.org/10.1136/heartjnl-2021-bcs.151" @default.
• W3172520466 hasPublicationYear "2021" @default.
• W3172520466 type Work @default.
• W3172520466 sameAs 3172520466 @default.
• W3172520466 citedByCount "0" @default.
• W3172520466 crossrefType "proceedings-article" @default.
• W3172520466 hasAuthorship W3172520466A5004676254 @default.
• W3172520466 hasAuthorship W3172520466A5012112944 @default.
• W3172520466 hasAuthorship W3172520466A5012346596 @default.
• W3172520466 hasAuthorship W3172520466A5012429282 @default.
• W3172520466 hasAuthorship W3172520466A5036372511 @default.
• W3172520466 hasAuthorship W3172520466A5036774695 @default.
• W3172520466 hasAuthorship W3172520466A5038761588 @default.
• W3172520466 hasAuthorship W3172520466A5043214675 @default.
• W3172520466 hasAuthorship W3172520466A5057585729 @default.
• W3172520466 hasAuthorship W3172520466A5063579369 @default.
• W3172520466 hasAuthorship W3172520466A5078715263 @default.
• W3172520466 hasAuthorship W3172520466A5087261864 @default.
• W3172520466 hasBestOaLocation W31725204661 @default.
• W3172520466 hasConcept C111566952 @default.
• W3172520466 hasConcept C126322002 @default.
• W3172520466 hasConcept C134018914 @default.
• W3172520466 hasConcept C164705383 @default.
• W3172520466 hasConcept C2775887513 @default.
• W3172520466 hasConcept C2775915353 @default.
• W3172520466 hasConcept C2777180221 @default.
• W3172520466 hasConcept C2778198053 @default.
• W3172520466 hasConcept C555293320 @default.
• W3172520466 hasConcept C71924100 @default.
• W3172520466 hasConcept C78085059 @default.
• W3172520466 hasConceptScore W3172520466C111566952 @default.
• W3172520466 hasConceptScore W3172520466C126322002 @default.
• W3172520466 hasConceptScore W3172520466C134018914 @default.
• W3172520466 hasConceptScore W3172520466C164705383 @default.
• W3172520466 hasConceptScore W3172520466C2775887513 @default.
• W3172520466 hasConceptScore W3172520466C2775915353 @default.
• W3172520466 hasConceptScore W3172520466C2777180221 @default.
• W3172520466 hasConceptScore W3172520466C2778198053 @default.
• W3172520466 hasConceptScore W3172520466C555293320 @default.
• W3172520466 hasConceptScore W3172520466C71924100 @default.
• W3172520466 hasConceptScore W3172520466C78085059 @default.
• W3172520466 hasLocation W31725204661 @default.
• W3172520466 hasOpenAccess W3172520466 @default.
• W3172520466 hasPrimaryLocation W31725204661 @default.
• W3172520466 hasRelatedWork W11304534 @default.
• W3172520466 hasRelatedWork W1372849 @default.
• W3172520466 hasRelatedWork W14674810 @default.
• W3172520466 hasRelatedWork W15094305 @default.
• W3172520466 hasRelatedWork W17607225 @default.
• W3172520466 hasRelatedWork W2770208 @default.
• W3172520466 hasRelatedWork W288983 @default.
• W3172520466 hasRelatedWork W400556 @default.
• W3172520466 hasRelatedWork W5695701 @default.
• W3172520466 hasRelatedWork W8231096 @default.
• W3172520466 isParatext "false" @default.
• W3172520466 isRetracted "false" @default.
• W3172520466 magId "3172520466" @default.
• W3172520466 workType "article" @default.